Clinical Trial Update: Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg≤20IU/ml or HBsAg Negative Without Serological Conversion [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 trial update evaluating the immunogenicity and safety of TVAX-008 injections in chronic hepatitis B patients with low or negative HBsAg who have n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• TVAX-008

Snippet

Sponsor: Grand Theravac Life Sciences (Nanjing) Co., Ltd. | Conditions: Chronic Hepatitis B | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING